Showing results (1381-1390 of 1,799) with videos related to

Sort By:
Pageof 180
Mabs|April 9, 2025
Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody-drug conjugateHwai Wen Chang, Gerhard Frey, Jing Wang, et al.
Mabs|April 1, 2025
Accelerating high-concentration monoclonal antibody development with large-scale viscosity data and ensemble deep learningLateefat A Kalejaye, Jia-Min Chu, I-En Wu, et al.
Mabs|May 13, 2025
Structural and biochemical differences between non-catalytic and catalytic antibodiesTaizo Uda, Ryuichi Kato, Yasuteru Shigeta, et al.
Mabs|May 10, 2025
Biologics developability data analysis using hierarchical clustering accelerates candidate lead selection, optimization, and preformulation screeningKevin James Metcalf, Galen Wo, Jan Paulo Zaragoza, et al.
Mabs|April 12, 2013
Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptidesDavid W LaFleur, Donara Abramyan, Palanisamy Kanakaraj, et al.
Mabs|April 12, 2013
High throughput solution-based measurement of antibody-antigen affinity and epitope binningPatricia Estep, Felicia Reid, Claire Nauman, et al.
Mabs|March 16, 2013
8(th) Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, SwitzerlandAlain Beck, Paul J Carter, Hans-Peter Gerber, et al.
Mabs|December 11, 2012
Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugatesMichael Ritchie, Lioudmila Tchistiakova, Nathan Scott
Mabs|December 11, 2012
Antagonist properties of monoclonal antibodies targeting human CD28: role of valency and the heavy-chain constant domainCaroline Mary, Flora Coulon, Nicolas Poirier, et al.
Mabs|December 11, 2012
Human TNF cytokine neutralization with a vNAR from Heterodontus francisci shark: a potential therapeutic useTanya Camacho-Villegas, Teresa Mata-Gonzalez, Jorge Paniagua-Solis, et al.
Pageof 180